Recent Reports


2010-01-25: Medical Research, Diagnostic Substances, Life Science Tools Report
7 leading Analysts; and top management from 2 Sector Firms examine this vital industry in this 38 page report from The Wall Street Transcript.
More Information
Order this Report

2009-12-07: Consumer Health Services Report
7 leading Analysts; and top management from 2 Sector Firm examine this vital industry in this 53 page report from The Wall Street Transcript.
More Information
Order this Report

2009-11-02: Pharmaceuticals Report
3 leading Analysts; and top management from 16 Sector Firms examine this vital industry in this 76 page report from The Wall Street Transcript.
More Information
Order this Report

2009-10-19: Biotechnology Report
3 leading Analysts; 2 Money Managers; and top management from 12 Sector Firms examine this vital industry in this 70 page report from The Wall Street Transcript.
More Information
Order this Report

09.21.09: Medical Real Estate: Healthcare REITs, Long-Term Care Facilities & Hospitals Report
3 analysts and 6 sector firms examine the medical real estate segment in this 45 page report from The Wall Street Transcript.
More Information
Order this Report

09.21.09: Medical Devices Report
4 analysts and 7 sector firms examine the medical devices segment in this 41 page report from The Wall Street Transcript.
More Information
Order this Report

09.14.09: Medical Research Services Report
2 analysts, and 4 sector firms examine the medical research services segment in this 23 page report from The Wall Street Transcript.
More Information
Order this Report

Search TWST Online

TWST Newsletter

Give us your email address and receive the TWST Newsletter.


Company Interview Excerpt
CEES VAN LEDE - AKZO NOBEL NV (AKZOY)


Full article published: 03/05/2001


For Subscribers

Get this article online now!

Order just this article
TWST: Could we start with a quick corporate profile, an introduction to the main businesses of Akzo Nobel?
Mr. van Lede: We presently have three major activities: pharmaceuticals, coatings and chemicals. In terms of profit contribution ' operating income ' well over 40% is pharma, and chemicals and coatings contribute the rest at almost equal levels; though it depends a little on the cycle. It could be a little bit more for coatings or a little bit more on chemicals. In terms of sales, 25% to 30% comes from pharmaceuticals, over 40% from coatings. In terms of employment, it's heavily slanted towards pharma because it is by far the most labour-intensive type of activity, and the investment is heavily slanted towards the chemicals, for obvious reasons.

TWST: The company has activities across a range of geographies; what are the most important ones for you?
Mr. van Lede: Presently, 55% of our sales are in Europe, in view of our origin, which is European ' Dutch, Swedish and German. We acquired Courtaulds and this company is based in the UK. We then have 25% in North America, and the remainder all over the world, with strong positions in Latin America, in Brazil in particular, and in Japan and Southeast Asia.

 

Tickers included in this excerpt: AKZOY

 

For more information call (212) 952 7433. The Wall Street Transcript does not endorse any of the comments made by interviewees, and does not make stock recommendations.